- জেনেরিক নাম
- Levetiracetam
- শক্তি
- 750 mg
- ডোজ ফর্ম
- Tablet
- প্রস্তুতকারক
- Renata PLC.
Epicet-750 XR Tablet Tablet
Epicet-750 XR Tablet সম্পর্কে
Epicet-750 XR Tablet হলো Levetiracetam-এর একটি ব্র্যান্ড, শক্তি ৭৫০ mg, ট্যাবলেট আকারে। Epicet-750 XR Tablet প্রস্তুত করেছে Renata PLC। Epicet-750 XR Tablet-এর সাথে Levetiracetam-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। এই তথ্য শুধু জানার জন্য; ঔষধ সবসময় ডাক্তারের পরামর্শ অনুযায়ী খাবেন, মাত্রা বা ব্র্যান্ড নিয়ে প্রশ্ন থাকলে ফার্মাসিস্টকে জিজ্ঞেস করুন।
Levetiracetam-এর ৩৪টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। সবচেয়ে কম দাম Citazar 250 mg Tablet-এর, প্রতি ইউনিট ৳ ১৫.১১।
Epicet-750 XR Tablet কী?
Epicet-750 XR Tablet is a prescription anti-epileptic medicine from Renata PLC. It contains levetiracetam 750 mg in an extended-release tablet form. It belongs to a group of medicines called adjunct anti-epileptic drugs. Doctors prescribe it for partial-onset seizures, which are seizures that start in one part of the brain. It can be used on its own in some patients or added to other epilepsy medicines. The extended-release form is designed to release the medicine gradually. The doctor decides the right dose and course for each person.
Epicet-750 XR Tablet-এর ব্যবহার
Epicet-750 XR Tablet is used to treat partial-onset seizures, with or without secondary generalisation. This means seizures that begin in one area of the brain and may spread to the whole brain. It may be prescribed alone for newly diagnosed epilepsy in some adults and adolescents. It can also be added to other anti-epileptic medicines for adults, adolescents and children with epilepsy. Your doctor will decide whether it is suitable for you.
Epicet-750 XR Tablet কীভাবে ব্যবহার করবেন
Take Epicet-750 XR Tablet exactly as your doctor tells you. Swallow the extended-release tablet whole; do not crush or chew it unless your doctor advises otherwise. The dose and course are decided by the doctor based on your condition and response. Do not change the dose or stop the medicine on your own, as stopping suddenly can worsen seizures. If you miss a dose, ask your doctor or pharmacist what to do. Keep the medicine out of reach of children.
Epicet-750 XR Tablet-এর পার্শ্বপ্রতিক্রিয়া
Like all medicines, Epicet-750 XR Tablet can cause side effects. In adults, the most common include sleepiness, weakness, infection and dizziness. Children may experience tiredness, aggression, nasal congestion, decreased appetite and irritability. Other side effects can occur. Tell your doctor if any side effect bothers you or does not go away. Seek medical help right away if you notice severe symptoms, such as a serious reaction or a sudden change in health.
সতর্কতা ও নিরাপত্তা
Do not take Epicet-750 XR Tablet if you are allergic to levetiracetam, other pyrrolidone derivatives, or any ingredient of the tablet. Tell your doctor if you have kidney or liver problems, as dose adjustment may be needed. The medicine is not recommended during pregnancy or in women who could become pregnant and are not using contraception unless the doctor considers it necessary. It passes into breast milk, so breastfeeding is not recommended unless the doctor decides it is needed. Always ask your doctor before starting or stopping this medicine.
সাধারণ প্রশ্ন
What side effects should I watch for, and when should I call the doctor?
Common side effects include sleepiness, weakness, infection and dizziness in adults. Children may have tiredness, aggression, nasal congestion, decreased appetite and irritability. Call your doctor if any side effect is severe, bothers you, or does not go away. Seek urgent help for serious reactions.
What is Epicet-750 XR Tablet used for and what kind of medicine is it?
It is an anti-epileptic medicine containing levetiracetam, used for partial-onset seizures with or without secondary generalisation. It may be used alone or with other epilepsy medicines. It is available as a 750 mg extended-release tablet. Your doctor will decide if it is right for you.
Who should avoid Epicet-750 XR Tablet or ask the doctor first?
Do not take it if you are allergic to levetiracetam, other pyrrolidone derivatives, or any ingredient. Ask your doctor first if you have kidney or liver problems, are pregnant or could become pregnant, or are breastfeeding. The doctor will decide whether it is suitable for you.
Can I stop taking Epicet-750 XR Tablet suddenly?
No. Stopping an anti-epileptic medicine suddenly can cause seizures to return or worsen. Always talk to your doctor before changing or stopping the medicine. The doctor will advise how to stop it safely if needed. Do not adjust the dose on your own.
নির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy-- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
মাত্রা ও সেবনবিধি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Adults and adolescents from 16 years of age: The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
ঔষধের মিথষ্ক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Antiepileptic medicinal products: Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
প্রতিনির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients.পার্শ্ব প্রতিক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Most common adverse reactions (incidence ≥ 5% more than placebo) include:- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
গর্ভাবস্থায় ও স্তন্যদানকালে
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary. Levetiracetam is excreted in human breast milk. Therefore, breastfeeding is not recommended. However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding. No impact on fertility was detected in animal studies. No clinical data are available, the potential risk for humans is unknown.সতর্কতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Renal impairment: The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection.Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
মাত্রাধিক্যতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses. After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specifc antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for levetiracetam and 74% for the primary metabolite.সংরক্ষণ
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Store at a cool temperature (not exceeding 25°C) and dry place, protected from light.বিকল্প ব্র্যান্ড: Levetiracetam
একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।
ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।